iShares MSCI Japan ETF vs GeneDx Holdings Corp — how do they compare? iShares MSCI Japan ETF trades at $97.71, while GeneDx Holdings Corp trades at $82.38 (market cap $2.44B). The key difference: iShares MSCI Japan ETF is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals.
| EWJ | WGS | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $96.97 | $167.51 |
52-Week Low | $77.93 | $34.51 |
Market Cap | — | $2.44B |
Enterprise Value | — | $2.48B |
Signals from Pluang's Aura AI — not financial advice
EWJ, the iShares MSCI Japan ETF, trades at $97.68, up 1.7% on the day, with a bullish technical signal driven by moving averages. The ETF's performance is influenced by Japan's economic policies, including recent U.S.-Japan yen intervention and domestic stimulus efforts. Key support sits at $96, while resistance is at $97, with the RSI indicating potential overbought conditions.
Outlook remains tied to Japan's economic reforms and currency stability, offering exposure to Japanese equities but with risks from yen volatility and inflation. Investor sentiment is cautious amid BOJ policy uncertainty, though institutional interest persists for diversification benefits.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Trailing returns across standard periods
EWJ tracks the MSCI Japan Index, providing broad exposure to over 180 large and mid-cap companies in Japan. It is the most established and liquid vehicle for accessing the Japanese equity market, featuring a diversified portfolio across industrials, consumer discretionary, and financial sectors.
Read more on EWJ →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →